West Pharma (WST) Tops Q3 EPS by 26c
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $362.31 -1.17%
Revenue Growth %: +2.6%
Financial Fact:
Cost of goods and services sold: 255.6M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +2.6%
Financial Fact:
Cost of goods and services sold: 255.6M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q3 EPS of $2.06, $0.26 better than the analyst estimate of $1.80. Revenue for the quarter came in at $706.5 million versus the consensus estimate of $687.09 million.
GUIDANCE:
West Pharma sees FY2021 EPS of $8.40-$8.50, versus the consensus of $8.21. West Pharma sees FY2021 revenue of $2.8-2.81 billion, versus the consensus of $2.8 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- UBS cuts KOSPI target by nearly 10% to reflect higher rates
- Nucor projects Q3 2026 earnings above prior year, below estimates
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
